In a post in the Center for Global Health Policy’s “Science Speaks” blog, Lucica Ditiu, executive secretary of the Stop TB Partnership, examines the need to include tuberculosis (TB) in the global AIDS response blueprint that Secretary of State Hillary Clinton announced at the XIX International AIDS Conference (AIDS 2012), writing, “At present one in four AIDS-related deaths is precipitated by TB. … All people living with HIV need to get tested for TB and receive TB treatment if they have the disease.” She continues, “We urge PEPFAR to include in the blueprint explicit TB/HIV indicators and activities,” and she provides five examples (10/23).
“An antibiotic used to treat severe bacterial infections showed promise at treating a highly drug-resistant and deadly form of tuberculosis [TB],” according to a study conducted by U.S. government and South Korean researchers and published in the New England Journal of Medicine on Wednesday, Reuters reports (Steenhuysen, 10/17). The “small study offers a bit of cautious optimism about the prospects for treatment of tuberculosis, … showing that adding a 12-year-old antibiotic called linezolid, brand name Zyvox, to existing treatments cured nearly 90 percent of patients with a form of tuberculosis resistant to both first- and second-line antibiotics,” NPR’s “Shots” blog writes (Knox, 10/18). “However, most of the patients [in the study] — 82 percent — experienced side effects while on the treatment, which tempered the findings, the team reported,” Reuters notes. “Researchers are desperately looking for new treatments for drug-resistant forms of TB, which threatens to derail progress in the global fight to eradicate the disease,” according to the news agency (10/17).
Noting the release of the WHO Global Tuberculosis Report 2012 this week, this Lancet editorial says the results show “good and bad news.” The editorial says, “The number of tuberculosis cases and deaths continues to fall … and overall, the world is on track to achieve the global target of a 50 percent reduction by 2015.” However, “with an estimated 8.7 million new cases (of which 13 percent represent co-infections with HIV) and 1.4 million deaths from tuberculosis in 2011,” the “global burden of tuberculosis remains huge,” the editorial states. The report also shows “alarming levels of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis,” the editorial notes.
Number Of New TB Infections Fall, But Drug Resistance, Lack Of Funding Could Slow Progress, WHO Reports
“New tuberculosis [TB] infections dropped 2.2 percent worldwide last year, but with nearly nine million new infections, the World Health Organization said TB remains a massive problem that could worsen if countries shortchange funding to fight it,” Reuters reports (Steenhuysen, 10/17). “In a new report issued Wednesday, the U.N. agency estimated there were about 8.7 million new cases of TB last year, down from about 8.8 million in 2010,” and “[t]he number of deaths was unchanged at about 1.4 million — making it the second-leading killer among infectious diseases after AIDS,” the Associated Press writes (Cheng, 10/17). “The number of people becoming ill with tuberculosis has been falling steadily for roughly a decade after a surge in the 1990s,” but “those numbers are still huge, and only 19 percent of those infected with forms of the disease that are resistant to multiple tuberculosis drugs are being diagnosed, the WHO estimated,” according to the Wall Street Journal (McKay, 10/18). BBC News notes the report “warned of ‘persistently slow progress’ in treating tuberculosis which is resistant to antibiotics” (Gallagher, 10/17).
“Researchers will find out early next year whether the first new vaccine against tuberculosis [TB] for 90 years protects against a disease that was once neglected but is now resurgent worldwide,” Financial Times reports. “Helen McShane, professor of vaccinology at Oxford University, said on Monday that clinical trial results of the MVA85A vaccine — developed in her laboratory over 10 years at a cost of Â£30 million [$48 million] — would be known in the first quarter of 2013,” the newspaper writes (Cookson, 10/15). “Today, most babies in the world are immunized with the old Bacille Calmette-Guerin (BCG) vaccine, first used in 1921,” PlusNews/IRIN writes. “Oxford’s vaccine, known as MVA85A, is designed to boost the effects of BCG,” the news service adds (10/16).
The Wall Street Journal examines how bureaucracy in India is slowing the treatment of tuberculosis (TB) in the country. The newspaper recounts the story of Rahima Sheikh, “one of 16 patients identified by Mumbai doctors to be resistant to virtually all traditional TB treatments.” The Wall Street Journal writes, “Mumbai officials have publicly pledged free treatment for Mrs. Sheikh and other, similar patients with extreme forms of drug resistance within the city’s jurisdiction,” but “Mrs. Sheikh has now become caught in the bureaucracy of India’s incomplete national network for treating the most virulent TB.”
South Africa “recently unveiled” a “newly reformed” South African National AIDS Council (SANAC), “coinciding with the announcement that the country has achieved universal access to HIV treatment,” PlusNews reports. Responding to a 2010 review of the body, SANAC “will now hold a new, annual meeting comprised of representatives from the research community, labor unions and people living with HIV,” at which “participants will discuss major policy issues and review progress on the country’s current national plan to address the twin epidemics of HIV and tuberculosis,” according to the news service.
In a BMJ Group Blogs post, Caroline Robinson, global health advocacy manager for Results U.K., discusses the prevalence and treatment of tuberculosis (TB) and drug-resistant TB in Europe and provides the example of Romania. She writes, “[E]vidence brought to light in a new report [.pdf] released recently outlining the effect funding shortages will have on HIV and TB, including drug-resistant TB, in the European region suggests that Romania does not have the institutional capacity to ensure its citizens have the basic right to health. The country relies on grants from the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which look set to end in 2013.” She continues, “[Global Fund] Board members should ensure that middle-income countries with epidemics among key populations can access critical Global Fund contributions and the E.U. and its member states must continue to provide the resources the fund requires to meet demand. Unless such support is given, countries like Romania will continue to fall further down the league tables in terms of treatment for this curable disease” (10/10).
“In an attempt to tackle tuberculosis [TB] among current and former miners, their families, and affected communities, 15 southern African leaders signed a Declaration on TB in the Mining Sector, a legal instrument, at the recent summit meeting of the Southern African Development Community (SADC) Heads of State and Government in Maputo, Mozambique,” the Lancet reports. “The declaration is to ensure commitment and accountability by member states to improve the lives of those affected by tuberculosis,” the journal writes, adding, “A code of conduct, to accompany the declaration, will be signed by the region’s health ministers next month.”
Secretary of State Hillary Clinton reflects on changes in U.S. global health diplomacy since taking office in this Global Health and Diplomacy opinion piece. “America had been leading the global health fight for decades,” but “we recognized that to sustain the impact of our work, we needed to change the way we did business,” she writes. “For example, while our agencies were providing tremendous leadership in isolation, they could still do more to collaborate effectively,” she writes, adding, “[W]e weren’t doing enough to coordinate our efforts with other donors or our partner countries,” and “we weren’t building sustainable systems to eventually allow our partner countries to manage more of their own health needs.” She says, “We were unintentionally putting a ceiling on the number of lives we could save.”